214 related articles for article (PubMed ID: 31966075)
1. Immunohistochemical-based molecular subtyping of colorectal carcinoma using maspin and markers of epithelial-mesenchymal transition.
Banias L; Jung I; Bara T; Fulop Z; Simu P; Simu I; Satala C; Gurzu S
Oncol Lett; 2020 Feb; 19(2):1487-1495. PubMed ID: 31966075
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal mixed adenoneuroendocrine carcinoma (MANEC): An immunohistochemistry study of 13 microsatellite stable cases.
Gurzu S; Fetyko A; Bara T; Banias L; Butiurca VO; Bara T; Tudorache V; Jung I
Pathol Res Pract; 2019 Dec; 215(12):152697. PubMed ID: 31704155
[TBL] [Abstract][Full Text] [Related]
3. Nuclear maspin expression: A biomarker for budding assessment in colorectal cancer specimens.
Banias L; Gurzu S; Kovacs Z; Bara T; Bara T; Jung I
Pathol Res Pract; 2017 Sep; 213(9):1227-1230. PubMed ID: 28780084
[TBL] [Abstract][Full Text] [Related]
4. Epithelial-mesenchymal transition (EMT) protein expression in a cohort of stage II colorectal cancer patients with characterized tumor budding and mismatch repair protein status.
Kevans D; Wang LM; Sheahan K; Hyland J; O'Donoghue D; Mulcahy H; O'Sullivan J
Int J Surg Pathol; 2011 Dec; 19(6):751-60. PubMed ID: 21791486
[TBL] [Abstract][Full Text] [Related]
5. Nuclear maspin expression correlates with the CpG island methylator phenotype and tumor aggressiveness in colorectal cancer.
Kim JH; Cho NY; Bae JM; Kim KJ; Rhee YY; Lee HS; Kang GH
Int J Clin Exp Pathol; 2015; 8(2):1920-8. PubMed ID: 25973084
[TBL] [Abstract][Full Text] [Related]
6. Subcellular Expression of Maspin in Colorectal Cancer: Friend or Foe.
Gurzu S; Jung I
Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33498377
[TBL] [Abstract][Full Text] [Related]
7. C4.4A is associated with tumor budding and epithelial-mesenchymal transition of colorectal cancer.
Oshiro R; Yamamoto H; Takahashi H; Ohtsuka M; Wu X; Nishimura J; Takemasa I; Mizushima T; Ikeda M; Sekimoto M; Matsuura N; Doki Y; Mori M
Cancer Sci; 2012 Jun; 103(6):1155-64. PubMed ID: 22404718
[TBL] [Abstract][Full Text] [Related]
8. From Dukes-MAC Staging System to Molecular Classification: Evolving Concepts in Colorectal Cancer.
Banias L; Jung I; Chiciudean R; Gurzu S
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012726
[TBL] [Abstract][Full Text] [Related]
9. Tumor budding at the invasive front of colorectal cancer may not be associated with the epithelial-mesenchymal transition.
Yamada N; Sugai T; Eizuka M; Tsuchida K; Sugimoto R; Mue Y; Suzuki M; Osakabe M; Uesugi N; Ishida K; Otsuka K; Matsumoto T
Hum Pathol; 2017 Feb; 60():151-159. PubMed ID: 27836787
[TBL] [Abstract][Full Text] [Related]
10. The Role of Galectin3, Tubulinβ, and Maspin in Promoting Tumor Budding in Colorectal Carcinoma and Their Clinical Implications.
Elkady N; Allam DM
Appl Immunohistochem Mol Morphol; 2024 Mar; 32(3):143-150. PubMed ID: 38251657
[TBL] [Abstract][Full Text] [Related]
11. Association Between the Immunohistochemistry Expression of E-cadherin, Beta-Catenin, and CD44 in Colorectal Adenocarcinoma.
Tunuguntla A; Suresh TN; Pn S
Cureus; 2023 Mar; 15(3):e35686. PubMed ID: 37012965
[TBL] [Abstract][Full Text] [Related]
12. Detailed analysis of epithelial-mesenchymal transition and tumor budding identifies predictors of long-term survival in pancreatic ductal adenocarcinoma.
Kohler I; Bronsert P; Timme S; Werner M; Brabletz T; Hopt UT; Schilling O; Bausch D; Keck T; Wellner UF
J Gastroenterol Hepatol; 2015 Mar; 30 Suppl 1():78-84. PubMed ID: 25827809
[TBL] [Abstract][Full Text] [Related]
13. Tumor budding and human chorionic gonadotropin-β expression correlate with unfavorable patient outcome in colorectal carcinoma.
Konishi Y; Kawamata F; Nishihara H; Homma S; Kato Y; Tsuda M; Kohsaka S; Einama T; Liu C; Yoshida T; Nagatsu A; Tanino M; Tanaka S; Kawamura H; Kamiyama T; Taketomi A
Med Oncol; 2018 Jun; 35(7):104. PubMed ID: 29892782
[TBL] [Abstract][Full Text] [Related]
14. Practical value of the new system for Maspin assessment, in colorectal cancer.
Gurzu S; Szentirmay Z; Popa D; Jung I
Neoplasma; 2013; 60(4):373-83. PubMed ID: 23581409
[TBL] [Abstract][Full Text] [Related]
15. Epithelial to mesenchymal transition markers are associated with an increased metastatic risk in primary cutaneous squamous cell carcinomas but are attenuated in lymph node metastases.
Toll A; Masferrer E; Hernández-Ruiz ME; Ferrandiz-Pulido C; Yébenes M; Jaka A; Tuneu A; Jucglà A; Gimeno J; Baró T; Casado B; Gandarillas A; Costa I; Mojal S; Peña R; de Herreros AG; García-Patos V; Pujol RM; Hernández-Muñoz I
J Dermatol Sci; 2013 Nov; 72(2):93-102. PubMed ID: 23928229
[TBL] [Abstract][Full Text] [Related]
16. Interaction of arylsulfatases A and B with maspin: A possible explanation for dysregulation of tumor cell metabolism and invasive potential of colorectal cancer.
Kovacs Z; Jung I; Szalman K; Banias L; Bara TJ; Gurzu S
World J Clin Cases; 2019 Dec; 7(23):3990-4003. PubMed ID: 31832401
[TBL] [Abstract][Full Text] [Related]
17. Expression of epithelial-mesenchymal transition and cancer stem cell markers in colorectal adenocarcinoma: Clinicopathological significance.
Choi JE; Bae JS; Kang MJ; Chung MJ; Jang KY; Park HS; Moon WS
Oncol Rep; 2017 Sep; 38(3):1695-1705. PubMed ID: 28677737
[TBL] [Abstract][Full Text] [Related]
18. TWIST1 and TWIST2 promoter methylation and protein expression in tumor stroma influence the epithelial-mesenchymal transition-like tumor budding phenotype in colorectal cancer.
Galván JA; Helbling M; Koelzer VH; Tschan MP; Berger MD; Hädrich M; Schnüriger B; Karamitopoulou E; Dawson H; Inderbitzin D; Lugli A; Zlobec I
Oncotarget; 2015 Jan; 6(2):874-85. PubMed ID: 25528769
[TBL] [Abstract][Full Text] [Related]
19. Differential membranous E-cadherin expression, cell proliferation and O-GlcNAcylation between primary and metastatic nodal lesion in colorectal cancer.
Jang TJ
Pathol Res Pract; 2016 Feb; 212(2):113-9. PubMed ID: 26724145
[TBL] [Abstract][Full Text] [Related]
20. Expression of E-cadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour-budding phenotype and suggests heterogeneity of stromal cells in pancreatic cancer.
Galván JA; Zlobec I; Wartenberg M; Lugli A; Gloor B; Perren A; Karamitopoulou E
Br J Cancer; 2015 Jun; 112(12):1944-50. PubMed ID: 25989272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
